Cargando…

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study

Tusamitamab ravtansine is an anti‐CEACAM5 antibody‐drug conjugate indicated in patients with solid tumors. Based on a previous developed semimechanistic model describing simultaneously pharmacokinetic (PK) of SAR408701, two of its active metabolites: DM4 and methyl‐DM4 and naked antibody, with integ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pouzin, Clemence, Tod, Michel, Chadjaa, Mustapha, Fagniez, Nathalie, Nguyen, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923727/ https://www.ncbi.nlm.nih.gov/pubmed/35191618 http://dx.doi.org/10.1002/psp4.12769

Ejemplares similares

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
por: Tabernero, Josep, et al.
Publicado: (2023)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
por: Schönfeld, Kurt, et al.
Publicado: (2017)

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
por: Schönfeld, Kurt, et al.
Publicado: (2018)

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
por: Santin, Alessandro D, et al.
Publicado: (2023)

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
por: Trnĕný, Marek, et al.
Publicado: (2018)

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
por: Blumenthal, Rosalyn D, et al.
Publicado: (2007)

Role of CEACAM1 and CEACAM20 in an In Vitro Model of Prostate Morphogenesis
por: Zhang, Hui, et al.
Publicado: (2013)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
por: Nadal-Serrano, Mercedes, et al.
Publicado: (2020)

A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta
por: Mavroudis, Panteleimon D., et al.
Publicado: (2022)

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
por: Pinkert, Jessica, et al.
Publicado: (2021)

CEACAMs: their role in physiology and pathophysiology
por: Kuespert, Katharina, et al.
Publicado: (2006)

Soluble CEACAM8 Interacts with CEACAM1 Inhibiting TLR2-Triggered Immune Responses
por: Singer, Bernhard B., et al.
Publicado: (2014)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021)

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
por: Quanz, Maria, et al.
Publicado: (2018)

Heterogeneity of CEACAM5 in breast cancer
por: Bechmann, Marc B., et al.
Publicado: (2020)

Interactions of pathogenic Escherichia coli with CEACAMs
por: Sheikh, Alaullah, et al.
Publicado: (2023)

CEACAM expression in an in-vitro prostatitis model
por: Kube-Golovin, Irina, et al.
Publicado: (2023)

CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production
por: Khairnar, Vishal, et al.
Publicado: (2015)

Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6
por: Chan, C.H.F., et al.
Publicado: (2007)

Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and recruitment of SHP-2 and c-Src
por: Müller, Mario M., et al.
Publicado: (2009)

Binding of Candida albicans to Human CEACAM1 and CEACAM6 Modulates the Inflammatory Response of Intestinal Epithelial Cells
por: Klaile, Esther, et al.
Publicado: (2017)

Regulation of CEACAM1 transcription in human breast epithelial cells
por: Gencheva, Marieta, et al.
Publicado: (2010)

Reversal of obesity development in Ceacam1 ( −/− ) male mice by bone marrow transplantation or introduction of the human CEACAM1 gene
por: Zhang, Zhifang, et al.
Publicado: (2022)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
por: Jeon, Eun-Jeong, et al.
Publicado: (2023)

CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas
por: Lee, Ok-Jun, et al.
Publicado: (2014)

CEACAM6 gene expression in intrahepatic cholangiocarcinoma
por: Ieta, K, et al.
Publicado: (2006)

CEACAM1: Expression and Role in Melanocyte Transformation
por: Turcu, Gabriela, et al.
Publicado: (2016)

CEACAM1-Mediated Inhibition of Virus Production
por: Vitenshtein, Alon, et al.
Publicado: (2016)

CEACAM1 promotes vascular aging processes
por: Kleefeldt, Florian, et al.
Publicado: (2020)

Structural analysis of human CEACAM1 oligomerization
por: Gandhi, Amit K., et al.
Publicado: (2022)

Integrin but not CEACAM receptors are dispensable for Helicobacter pylori CagA translocation
por: Zhao, Qing, et al.
Publicado: (2018)

The CEACAM1 N-terminal Ig domain mediates cis- and trans-binding and is essential for allosteric rearrangements of CEACAM1 microclusters
por: Klaile, Esther, et al.
Publicado: (2009)

Liver-specific rescuing of CEACAM1 reverses endothelial and cardiovascular abnormalities in male mice with null deletion of Ceacam1 gene
por: Russo, Lucia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_45q58gil0tojvan1e8s3as94fi